PKY.AX Pathkey.AI up 38.10% intraday on ASX 18 Feb 2026: catalysts to watch

PKY.AX stock jumped 38.10% intraday to A$0.029 on the ASX in Australia, led by a surge in volume of 5,521,447 shares as traders reacted to near-term catalysts. The move lifts Pathkey.AI Ltd (PKY.AX) well above its 50-day average of A$0.01838 and its 200-day average of A$0.02094. Market attention is focused on upcoming earnings and trial partnerships after the company rebranded in August 2025, and the stock’s relative strength today signals short-term momentum for active traders.

PKY.AX stock intraday snapshot

PKY.AX stock is trading on the ASX at A$0.029, up A$0.008 from the previous close of A$0.021, with a day range of A$0.025–A$0.033. Volume is 5,521,447, well above average volume 722,003, showing elevated trader interest in this healthcare AI name.

What is driving the gain

The intraday rally follows renewed investor focus on Pathkey.AI’s TrialKey platform and an approaching earnings announcement scheduled for 25 Feb 2026. Positive sector flows into Healthcare innovation stocks and a pick-up in small-cap momentum on the ASX also contributed to the move.

Financials and valuation: quick view

Pathkey.AI reports EPS of -0.01 and a negative PE of -2.30, reflecting losses across the trailing twelve months. Market cap stands at A$8,155,892, price-to-sales is 20.51, and the current ratio is 0.77, highlighting tight short-term liquidity for a small-cap developer of clinical-trial AI.

Technical picture and trading flow

Momentum indicators show RSI 55.89 and ADX 49.60, suggesting a strong intraday trend, while on-balance volume is negative historically but today’s spike reversed intraday flows. The stock is above both the 50-day A$0.01838 and 200-day A$0.02094 averages, which supports short-term bullish traders.

Meyka AI grade and forecast for PKY.AX stock

Meyka AI rates PKY.AX with a score out of 100: 65.22 / Grade B / Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly target of A$0.060, implying 103.45% upside from the current A$0.029, and a monthly projection of A$0.020, implying -31.03% downside. Forecasts are model-based projections and not guarantees.

Price targets, risks and opportunities

Given no consensus analyst price target, a scenario-based short-term price target is A$0.05 based on successful trial partnerships and revenue traction, implying 72.41% upside from A$0.029. Key risks include continued negative EPS, tight liquidity with cash per share A$0.00219, and high price-to-sales of 20.51 that magnify downside if trials stall.

Final Thoughts

PKY.AX stock’s 38.10% intraday jump to A$0.029 on 18 Feb 2026 reflects speculative repositioning ahead of an earnings update and stronger interest in healthcare AI names on the ASX. The move is supported by volume at 5,521,447 shares, above the 50-day and 200-day averages. Fundamental metrics remain mixed: EPS is -0.01, PE is -2.30, price-to-sales is 20.51, and the current ratio is 0.77, so any sustained rally requires operational progress or revenue signs. Meyka AI’s model projects a quarterly price of A$0.060, implying 103.45% upside from the current price, while the monthly projection of A$0.020 implies -31.03% downside. These divergent model outputs underscore the stock’s volatility and the binary nature of small-cap clinical AI plays. For traders, the intraday strength creates short-term opportunities; for investors, outcomes hinge on upcoming earnings, trial milestones, and cash runway. Follow company releases on the official site and ASX filings for confirmation of catalysts, and review PKY.AX stock metrics on our platform for real-time updates. Sources: Pathkey.AI and ASX company page. Internal data and screening available at PKY.AX at Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.